Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming Bernard Durkan .
Filed returns
39
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Invite to Leinster House briefing on the burden of influenza in Ireland (Public policy or programme) | 15 | On lobbying.ie |
| May–Aug 2024 | Hanover Media Strategy Limited | Health | Request for AV room sponsorship - Influenza Briefing (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Invitation to a roundtable discussion on the challenges and pressures posed by influenza on the Irish health system, with a particular focus on the over 65s population. (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 23 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 10 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | The landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 12 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Transport | The impact of vehicle supply shortages on the car rental sector (Public policy or programme) | 10 | On lobbying.ie |
| May–Aug 2022 | Hanover Media Strategy Limited | Transport | Shared Pre-Budget 2023 submission to inform policy on shared transport, electrification and vehicle supply (Public policy or programme) | 29 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Finance | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Finance | Consumer protection for SMEs whose loans have been sold to unregulated entities (Legislation) | 12 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 9 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 85 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Legislation) | 4 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines (Matters involving public funds) | 10 | On lobbying.ie |
| Sep–Dec 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 10 | On lobbying.ie |
| May–Aug 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 13 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Creation of national policy to increase availability of Orphan Medicinal Products (Legislation) | 8 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 18 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Rare Disease Medicines (Public policy or programme) | 11 | On lobbying.ie |
| Jan–Apr 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 19 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 34 | 87.2% | |
| Transport | 3 | 7.7% | |
| Finance | 2 | 5.1% |